Magle Biopharma

Magle Biopharma is a Swedish healthcare company that specializes in the development and manufacturing of innovative medical devices and pharmaceutical products using its proprietary Degradable Starch Microspheres (DSM) technology platform. The company operates as a fully integrated entity, offering Contract Development and Manufacturing Organization (CDMO) services alongside its internal product pipeline. Its core technology enables controlled drug delivery and effective surgical solutions, with a focus on areas such as wound care, surgery, and diagnostics. Magle Biopharma is publicly traded and maintains a strong presence in the European life sciences sector through its acquisition of Chemoswed, which expanded its chemical synthesis and manufacturing capabilities.